INVESTORS

Corporate Profile

Dyadic Applied BioSolutions (NASDAQ: DYAI)

We are a global biotechnology company focused on the large-scale production of high-value, strategic input proteins for non-pharmaceutical applications across the life sciences, food & nutrition, and bioindustrial sectors. These proteins serve as essential components in bioprocessing, formulation, and product development – enabling innovation without the regulatory complexity and high costs associated with therapeutic biologics.

Company Contact

PING W. RAWSON
Email: ir@dyadic.com
Phone: 561-743-8333

Transfer Agent

Continental Stock Transfer & Trust
1 State St., 30th Floor
New York, NY 10004-1561
212-509-4000 or 800-509-5586

About Dyadic International, Inc.

Dyadic International, Inc. is a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective, affordable, and accessible biopharmaceutical products for human and animal health.

Dyadic’s gene expression and protein production platforms are based on the highly productive and scalable fungus Thermothelomyces heterothallica (formerly Myceliophthora thermophila). Our lead technology, C1-cell protein production platform, is based on an industrially proven microorganism (named C1), which is currently used to speed development, lower production costs, and improve performance of biologic vaccines and drugs at flexible commercial scales for the human and animal health markets.

Dyadic has also developed the Dapibus™ filamentous fungal based microbial protein production platform to enable the rapid development and large-scale manufacture of low-cost proteins, metabolites, and other biologic products for use in non-pharmaceutical applications, such as food, nutrition, and wellness.